CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
+$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$7.06M |
| 3 |
NVIDIA
NVDA
|
+$6.46M |
| 4 |
Microsoft
MSFT
|
+$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
+$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
+$5.72M |
| 2 |
GSK
GSK
|
+$5.14M |
| 3 |
Pinduoduo
PDD
|
+$3.46M |
| 4 |
Procter & Gamble
PG
|
+$2.91M |
| 5 |
Synopsys
SNPS
|
+$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
MongoDB
MDB
$26.3B
| $280K | 0.03% |
1,202
+265
| +28% | +$61.7K |
|
302
Arvinas
ARVN
$583M
| $279K | 0.03% |
14,570
+1,367
| +10% | +$26.2K |
|
303
Novavax
NVAX
$1.26B
| $273K | 0.03% |
33,965
+3,174
| +10% | +$25.5K |
|
304
Aurinia Pharmaceuticals
AUPH
$1.62B
| $273K | 0.03% |
30,359
+2,857
| +10% | +$25.7K |
|
305
Day One Biopharmaceuticals
DAWN
$765M
| $271K | 0.03% |
21,383
+2,180
| +11% | +$27.6K |
|
306
Invesco QQQ Trust
QQQ
$370B
| $262K | 0.02% |
511
+176
| +53% | +$90.1K |
|
307
Viking Holdings
VIK
$28.3B
| $257K | 0.02% |
5,844
| – | – |
|
308
Ardelyx
ARDX
$1.59B
| $255K | 0.02% |
50,222
+4,942
| +11% | +$25.1K |
|
309
Harrow
HROW
$1.47B
| $253K | 0.02% |
7,552
+727
| +11% | +$24.4K |
|
310
Intellia Therapeutics
NTLA
$1.27B
| $252K | 0.02% |
21,596
+2,059
| +11% | +$24K |
|
311
Snowflake
SNOW
$75.6B
| $250K | 0.02% |
+1,622
| New | +$250K |
|
312
Immunocore
IMCR
$1.85B
| $248K | 0.02% |
8,393
+960
| +13% | +$28.3K |
|
313
ANI Pharmaceuticals
ANIP
$2.06B
| $246K | 0.02% |
4,457
+412
| +10% | +$22.8K |
|
314
Rocket Pharmaceuticals
RCKT
$352M
| $243K | 0.02% |
19,329
+1,824
| +10% | +$22.9K |
|
315
Syndax Pharmaceuticals
SNDX
$1.41B
| $239K | 0.02% |
18,099
+1,732
| +11% | +$22.9K |
|
316
Enliven Therapeutics
ELVN
$1.19B
| $233K | 0.02% |
10,360
+1,275
| +14% | +$28.7K |
|
317
Innoviva
INVA
$1.29B
| $230K | 0.02% |
13,274
+1,241
| +10% | +$21.5K |
|
318
Wayfair
W
$11.3B
| $220K | 0.02% |
+4,974
| New | +$220K |
|
319
ARS Pharmaceuticals
SPRY
$1.06B
| $217K | 0.02% |
20,607
+1,962
| +11% | +$20.7K |
|
|
AVDL
320
Avadel Pharmaceuticals
AVDL
$1.49B
| $215K | 0.02% |
20,432
+1,916
| +10% | +$20.1K |
|
321
Vir Biotechnology
VIR
$721M
| $214K | 0.02% |
29,202
+2,922
| +11% | +$21.4K |
|
322
Zymeworks
ZYME
$1.15B
| $214K | 0.02% |
14,605
+940
| +7% | +$13.8K |
|
323
Replimune Group
REPL
$471M
| $198K | 0.02% |
16,317
+3,177
| +24% | +$38.5K |
|
324
Collegium Pharmaceutical
COLL
$1.19B
| $196K | 0.02% |
6,838
+642
| +10% | +$18.4K |
|
325
uniQure
QURE
$956M
| $195K | 0.02% |
11,062
+969
| +10% | +$17.1K |
|